<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="148965">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01161121</url>
  </required_header>
  <id_info>
    <org_study_id>Rega-9I06</org_study_id>
    <nct_id>NCT01161121</nct_id>
  </id_info>
  <brief_title>Regadenoson to Achieve Maximal Hyperemia for Fractional Flow Reserve in the Catheterization Lab</brief_title>
  <official_title>Utilization of Lexiscan (Regadenoson)in the Cardiac Catheterization Lab to Achieve Maximal Hyperemia for Coronary Physiologic Assessment With Fractional Flow Reserve</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Louis University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Astellas Pharma US, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>St. Louis University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if regadenoson is as safe and effective as
      adenosine when used in the cardiac catheterization lab during measurement of coronary flow
      reserve and fractional flow reserve. The study hypothesis is the assessment of Fractional
      Flow Reserve (FFR) in the catheterization lab can be performed with equivalent accuracy when
      hyperemia is induced with IV Regadenoson compared with IV Adenosine without compromising
      patient safety.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2010</start_date>
  <completion_date type="Anticipated">August 2013</completion_date>
  <primary_completion_date type="Anticipated">May 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in FFR and Coronary Flow Reserve measurements between IV adenosine and IV regadenoson</measure>
    <time_frame>Every 30 seconds during infusion through 5 minutes post infusion of adenosine and regadenoson.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Monitor for potential side effects after IV adenosine and IV regadenoson administration such as chest pain, headache, flushing, nausea or arrhythmias</measure>
    <time_frame>Every 30 seconds during infusion through 5 minutes post infusion</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Adenosine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Adenosine infusion will be compared to Regadenoson for safety/side effects. Arterial blood pressure, coronary pressure, heart rate, oxygen saturation and coronary flow, FFR, and coronary flow velocity will be assessed. Safety will be assessed by monitoring for any side effects such as chest pain, headache, flushing, nausea, or arrhythmias.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regadenoson</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Once the mean coronary flow velocity returns to within 15% pre-dose value then Regadenoson IV injection will be given at 0.4 mg 5/ml- 0.08mg/ml. Then, a 5 cc saline flush will be administered.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>adenosine</intervention_name>
    <description>Measuring FFR and Coronary Flow Reserve after administration of IV adenosine 140 mcg/kg/min for 2 minutes.</description>
    <arm_group_label>Adenosine</arm_group_label>
    <other_name>Adenoscan(adenosine)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>regadenoson</intervention_name>
    <description>Measuring FFR and Coronary Flow Reserve after administration of IV regadenoson 0.4 mg over 10 seconds.</description>
    <arm_group_label>Adenosine</arm_group_label>
    <arm_group_label>Regadenoson</arm_group_label>
    <other_name>Lexiscan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adenosine</intervention_name>
    <description>Injection of IV Adenosine for 2 minutes at rate of 140mg/kg to dilate coronary arteries and provoke maximal hyperemia</description>
    <arm_group_label>Adenosine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male or female patients greater than 18 years old (If female, pt. must be
             post-menopausal, surgically sterile, or be non-pregnant as determined by a negative
             urine or serum B-HCG pregnancy test within 24 hours prior to enrollment.

          -  Provided written consent approved by Institutional Review Board and provided HIPAA
             authorization

          -  Have at least one coronary stenosis (greater or equal to 40% but less than 70&amp;
             narrowing by visual inspection) and technically accessible coronary artery into which
             the pressure wire may be introduced.

        Exclusion Criteria:

          -  ST elevation myocardial infarction

          -  Cardiogenic shock

          -  Pregnancy

          -  Total vessel occlusion

          -  Extremely tortuous coronary arteries

          -  Second and third degree heart block without pacemaker

          -  Severe chronic obstructive pulmonary disease and active bronchospasm

          -  Less than age 18 years

          -  Have received theophylline, aminophylline, pentoxifylline or dipyridamole within 12
             hours of FFR measurement.

          -  Has severe 3 vessel disease defined by &gt;80% luminal narrowing by visual inspection

          -  Known hypersensitivity to adenosine or regadenoson

          -  Recent uncontrolled ventricular arrhythmia

          -  History of greater than Type I atrioventricular block, symptomatic resting
             bradycardia, sick sinus syndrome (without permanent pacemaker)

          -  History of heart transplantation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael J Lim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Louis University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael J Lim, MD</last_name>
    <phone>314-268-7992</phone>
    <email>limmj@slu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Joshua Stolker, MD</last_name>
    <phone>314-268-5172</phone>
    <email>jstolker@slu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin M Zenni II, MD</last_name>
      <phone>904-244-3378</phone>
    </contact>
    <investigator>
      <last_name>Martin M Zenni II, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bharat Gummadi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dominick Angiolillo, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lyndon Box, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luis Guzman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Theodore Bass, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Louis University</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chris Uhles, RN</last_name>
      <phone>314-577-8876</phone>
      <phone_ext>2</phone_ext>
      <email>ctaaffe1@slu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Liz Weber, RN</last_name>
      <phone>314-577-8876</phone>
      <phone_ext>3</phone_ext>
      <email>eweber1@slu.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Joshua Stolker, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robert Neumayr, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bryan Piotrowski, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robert Armbruster, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zainal Hussain, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Steven Rough, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Pijls NH, Van Gelder B, Van der Voort P, Peels K, Bracke FA, Bonnier HJ, el Gamal MI. Fractional flow reserve. A useful index to evaluate the influence of an epicardial coronary stenosis on myocardial blood flow. Circulation. 1995 Dec 1;92(11):3183-93.</citation>
    <PMID>7586302</PMID>
  </reference>
  <reference>
    <citation>Iskandrian AE, Bateman TM, Belardinelli L, Blackburn B, Cerqueira MD, Hendel RC, Lieu H, Mahmarian JJ, Olmsted A, Underwood SR, Vitola J, Wang W; ADVANCE MPI Investigators.. Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: results of the ADVANCE phase 3 multicenter international trial. J Nucl Cardiol. 2007 Sep-Oct;14(5):645-58.</citation>
    <PMID>17826318</PMID>
  </reference>
  <reference>
    <citation>Tonino PA, De Bruyne B, Pijls NH, Siebert U, Ikeno F, van' t Veer M, Klauss V, Manoharan G, Engstr√∏m T, Oldroyd KG, Ver Lee PN, MacCarthy PA, Fearon WF; FAME Study Investigators.. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med. 2009 Jan 15;360(3):213-24. doi: 10.1056/NEJMoa0807611.</citation>
    <PMID>19144937</PMID>
  </reference>
  <reference>
    <citation>Lim MJ, Kern MJ. Coronary pathophysiology in the cardiac catheterization laboratory. Curr Probl Cardiol. 2006 Aug;31(8):493-550. Review.</citation>
    <PMID>16920478</PMID>
  </reference>
  <verification_date>November 2012</verification_date>
  <lastchanged_date>November 13, 2012</lastchanged_date>
  <firstreceived_date>July 6, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>St. Louis University</investigator_affiliation>
    <investigator_full_name>Michael J. Lim</investigator_full_name>
    <investigator_title>Director, Division of Cardiology</investigator_title>
  </responsible_party>
  <keyword>Fractional flow reserve</keyword>
  <keyword>adenosine</keyword>
  <keyword>regadenoson</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Hyperemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adenosine</mesh_term>
    <mesh_term>Regadenoson</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
